Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to show how the body absorbs, metabolises and excretes the drug [14C]AZD0530. As for all clinical trials, safety and tolerability of the drug will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [14C] AZD0530 | Drug | Solution, Oral, once |
| Measure | Description | Time Frame |
|---|---|---|
| To characterise the absorption, metabolism and excretion of a single oral dose of 400mg [14C]AZD0530 | Multiple PK, Urine and faeces samples taken between predose to 240 hours post dose |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the safety profile by assessment of adverse events, physical examination, pulse, blood pressure, clinical chemistry, haematology, urinalysis & ECG | From time of consent to last visit |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Raj Chetty, MD | AstraZeneca, Clinical Pharamcology Unit, Alderley Park | Principal Investigator |
| Mary Stuart, MD | AstraZeneca, Parklands, Alderley Park | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Alderley Park | Cheshire | United Kingdom |
Not provided
| ID | Term |
|---|---|
| C515233 | saracatinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided